Palandri F.; Polverelli N.; Catani L.; Sollazzo D.; Ottaviani E.; Parisi S.; Baccarani M.; Vianelli N., Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients, «BRITISH JOURNAL OF HAEMATOLOGY», 2012, 156, pp. 281 - 284 [articolo]
Palandri F.; Polverelli N.; Catani L.; Ottaviani E.; Baccarani M.; Vianelli N., Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years, «BRITISH JOURNAL OF HAEMATOLOGY», 2012, 156, pp. 676 - 679 [articolo]
Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S;
Giugliano E; Albano F; Cuneo A;Abruzzese E; Martino B; Palandri F;
Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G, Deletionsof the derivative chromosome 9 do not influence the response
and the outcomeof chronic myeloid leukemia in early chronic phase
treated with imatinibmesylate: GIMEMA CML Working Party analysis, «JOURNAL OF CLINICAL ONCOLOGY», 2010, 28(16), pp. 2748 - 2754 [articolo]
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G., Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib, «LEUKEMIA RESEARCH», 2010, 34(2), pp. 143 - 147 [articolo]
Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N., Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy, «LEUKEMIA RESEARCH», 2009, 33, pp. e218 - e220 [articolo]
Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G., Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors., «BLOOD», 2009, 114, pp. 2168 - 2171 [articolo]
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia, Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up, «HAEMATOLOGICA», 2008, 93(12), pp. 1792 - 1796 [articolo]
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; GIMEMA Working Party on CML., Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome, «HAEMATOLOGICA», 2008, 93(5), pp. 770 - 774 [articolo]
Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML., Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML., «JOURNAL OF CLINICAL ONCOLOGY», 2008, 26, pp. 106 - 111 [articolo]
Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M., Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis., «BONE MARROW TRANSPLANTATION», 2007, 39, pp. 189 - 191 [articolo]
Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandri F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G., Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party., «HAEMATOLOGICA», 2007, 92, pp. 101 - 105 [articolo]
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, «HAEMATOLOGICA», 2007, 92, pp. 401 - 404 [articolo]
Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G., Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies, in: , «HAEMATOLOGICA», 2006, 91(s3), pp. 31 - 31 (atti di: IX congresso della Società Italiana di Ematologia Sperimentale (SIES)., Napoli, Italy, 20-22/09/2006) [atti di convegno-abstract]
Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G., Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies, in: , «HAEMATOLOGICA», 2006, 91(s1), pp. 27 - 27 (atti di: 11th Meeting of the European Hematology Association (EHA)., Amsterdam (Netherlands), 15-18/06/2006) [atti di convegno-abstract]
BONIFAZI F.; BANDINI G.; STANZANI M.; PALANDRI F.; GIANNINI B.; ARPINATI M.; ROSTI G.; BACCARANI M., In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study., «BONE MARROW TRANSPLANTATION», 2005, 35, pp. 1025 - 1026 [articolo]
